Major Pharmaceutical Deals in 2026
Pharma Acquisitions Watch: Seventeen 2026 Deals Making Waves
In 2026, the pharmaceutical industry is experiencing a wave of strategic acquisitions that are actively reshaping its future. While a handful of high-profile deals have captured headlines, several other transactions are steadily gaining traction and drawing keen attention from investors and market analysts.
Here’s a snapshot of fourteen standout acquisitions from 2026 that are creating notable momentum in the market. From biotech breakthroughs to pipeline expansions and market consolidations, these deals reflect the global pharma landscape's evolving priorities and competitive dynamics.
Licensing Deals Gaining Traction in Pharma
The 2026 deal landscape shows a clear shift toward high-value, innovation-led partnerships, with strong activity in oncology and metabolic disorders (obesity and diabetes). Large deals—such as Eli Lilly’s $8.5 billion agreement and AbbVie’s $4.95 billion oncology deal—highlight intense competition in these high-growth areas.
There is also a growing focus on advanced technologies, including AI-driven drug discovery, RNA therapeutics, and siRNA platforms, indicating a move toward faster and more precise drug development.
Overall, pharma companies are prioritizing next-generation therapies and platform technologies, with mega-deals concentrated in key therapeutic areas while smaller deals target early-stage innovation and niche indications.
Strategic Collaborations: R&D Deals Shaping the Future of Pharma
In addition to high-profile acquisitions, 2026 is witnessing a surge in strategic research and development collaborations that are capturing industry attention. These partnerships are not only accelerating innovation but also enabling companies to pool expertise, technology platforms, and resources to target complex diseases.
Among the standout deals are:
- Teva Pharmaceuticals and Blackstone Life Sciences – Duvakitug In March 2026, Teva Pharmaceuticals entered into a strategic agreement with Blackstone Life Sciences to advance Duvakitug, a monoclonal antibody being developed for multiple indications. Under the terms of the deal, Blackstone Life Sciences committed $400 million to support the development and commercialization of the therapy. The collaboration reflects Teva’s continued focus on strengthening its innovative biologics pipeline and expanding treatment options across several therapeutic areas.
- Bio-Sourcing and Zerion Pharma – Oral Trastuzumab Formulation In January 2026, Bio‑Sourcing partnered with Zerion Pharma A/S to develop an oral formulation of trastuzumab, a monoclonal antibody widely used in the treatment of breast cancer. The agreement, valued at €1.3 million, aims to leverage Zerion’s drug-delivery technology to create a more patient-friendly oral version of the established oncology therapy, potentially improving treatment accessibility and convenience.
- Teva Pharmaceuticals and Royalty Pharma – TEV-408 Also in January 2026, Teva Pharmaceuticals entered into a financing agreement with Royalty Pharma plc for the development of TEV-408, an anti-IL-15 monoclonal antibody being investigated for the treatment of vitiligo and other skin disorders. The deal is valued at $500 million, providing substantial funding to support the advancement of the therapy through clinical development while reinforcing Teva’s commitment to expanding its immunology and dermatology portfolio.